• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.15% Nasdaq Up0.36%

    Halozyme Therapeutics, Inc. (HALO)

    -NasdaqGS
    9.46 Up 0.44(4.88%) 4:00PM EST
    |After Hours : 9.46 0.00 (0.00%) 5:00PM EST
    Add to Portfolio
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingDec 31, 2013Dec 31, 2012Dec 31, 2011
    Total Revenue 54,799   42,325   56,086  
    Cost of Revenue6,246  1,094  258  
    Gross Profit 48,554   41,231   55,829  
    Operating Expenses
    Research Development96,640  70,044  57,563  
    Selling General and Administrative32,348  24,812  18,104  
    Non Recurring -   -   -  
    Others -   -   -  
    Total Operating Expenses -   -   -  
    Operating Income or Loss (80,434) (53,625) (19,839)
    Income from Continuing Operations
    Total Other Income/Expenses Net229  73  69  
    Earnings Before Interest And Taxes(80,204)(53,552)(19,770)
    Interest Expense3,274   -   -  
    Income Before Tax(83,479)(53,552)(19,770)
    Income Tax Expense -   -   -  
    Minority Interest -   -   -  
    Net Income From Continuing Ops(83,479)(53,552)(19,770)
    Non-recurring Events
    Discontinued Operations -   -   -  
    Extraordinary Items -   -   -  
    Effect Of Accounting Changes -   -   -  
    Other Items -   -   -  
    Net Income (83,479) (53,552) (19,770)
    Preferred Stock And Other Adjustments -   -   -  
    Net Income Applicable To Common Shares (83,479) (53,552) (19,770)

    Sign Up for a Free Trial to EDGAR Online Premium!
    Get the critical business and financial information you need for more than 15,000 U.S. public companies.
    Sign Up Now - Learn More

    Currency in USD.